Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DXA023
- Development stage
- Unknown
- Lead developer
- Hangzhou DAC Biotech
- Modality
- Antibody-Based Therapeutics
01
Overview
DXA023: sourced facts only. name: "DXA023 exhibits specific and high-affinity binding to human PD-1 and VEGF." [DOI:10.1158/1538-7445.am2025-2864]; target: "DXA023 exhibits specific and high-affinity binding to human PD-1 and VEGF." [DOI:10.1158/1538-7445.am2025-2864]; developer: "Hangzhou DAC Biotechnology Co., Ltd., Hangzhou, China." [DOI:10.1158/1538-7445.am2025-2864]; modality: "DXA023, the bispecific antibody, possesses a tetravalent structure similar to Ivonescimab, demonstrated both efficacy and safety against both PD-L1 and VEGF targets." [DOI:10.1158/1538-7445.am2025-2864]
02
Targets
Beyond the preview
Go deeper on DXA023.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DXA023.